all stories

The drug lenacapavir is a mighty weapon against HIV. Its rollout gets mixed reviews

Fadingwire flash3 outlets reported this themselves; 7 of 10 reports ran a copy, most inside an hour.
original reportingcopies
Thu, 13 August 2026peak 8 reports on Thu, 13 August 2026Fri, 21 August 2026

What it is about

Goldiano KivumbiEmax KintuAsia RussellMichal RuprechtMatovu KiweewaRonald MusiitwaAmiri KabuyeFlavia Matovu KiweewaGoldiano KigandaMartin MatovuWayne State University School Of MedicinePulitzer CenterInstagramStanford Global Health MediaClinton Health Access InitiativeMinistry Of HealthHealth Global AccessDoctors Without BordersGlobal Fund To FightDrug Administration

Who published it, and when

original reportcopyfirst to report
wutc.org1 copy echoing NPR News
wvtf.org1 copy echoing NPR News
wnmufm.org1 copy echoing NPR News
kgou.org1 copy echoing NPR News
interlochenpublicradio.org1 copy echoing NPR News
wvik.org1 copy echoing NPR News
kacu.org1 copy echoing NPR News
mwnation.com1 original report
13 Aug, 11:18over 3 days16 Aug, 04:09

2 reports left out of the cascade - too little in common with the story to place

How it spread - 3 original reports, 7 reprints

  1. Thu, 13 August 2026

    1 report
  2. Sun, 16 August 2026

    1 report
    • mwnation.com04:09first to report

      Since its rollout on July 1, lenacapavir, a long‑acting HIV prevention injection that offers up to six months of protection, has already reached 2 000 people across Malawi. The demand to access the jab is steadily rising, especially among the youths between the age of 25 and 35, according to Ministry of Health and Sanitation. …

  3. Fri, 21 August 2026

    1 report

One email a week

The stories everytrace watched stay alive - how many independent outlets carried each one, and how long it lasted. No daily digest, no breaking-news alerts.